% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Rathke:147386,
author = {H. Rathke and T. Holland-Letz$^*$ and W. Mier and P.
Flechsig and E. Mavriopoulou and M. Röhrich and K.
Kopka$^*$ and M. Hohenfellner and F. L. Giesel and U. A.
Haberkorn$^*$ and C. Kratochwil},
title = {{R}esponse prediction of 177{L}u-{PSMA}-617 {RLT} using
{PSA}, {C}hromogranin {A}, and {LDH}.},
journal = {Journal of nuclear medicine},
volume = {61},
number = {5},
issn = {2159-662X},
address = {New York, NY},
publisher = {Soc.},
reportid = {DKFZ-2019-02503},
pages = {689-695},
year = {2020},
note = {2020 May;61(5):689-695},
abstract = {Neuroendocrine-like trans-differentiation of prostate
cancer adenocarcinomas correlates with serum levels of
Chromogranin A (CgA) and drives treatment resistance. Aim of
this work was to evaluate whether CgA could serve as a
response predictor for 177Lu-PSMA617 radio-ligand therapy
(PSMA-RLT) in comparison to the established tumor markers.
Methods: 100 consecutive patients with metastasized
castration resistant prostate cancer (mCRPC) scheduled for
PSMA-RLT were evaluated for prostate specific antigen (PSA),
lactate dehydrogenase (LDH) and CgA at baseline and in
follow-up of PSMA-RLT. Tumor-uptake of PSMA-ligand, a known
predictive marker for response, was assessed as a
control-variable. Results: From the 100 evaluated patients,
35 had partial remission (PR), 16 stable disease (SD), 15
mixed response (MR) and 36 progression of disease (PD). High
tumor-uptake (above salivary gland uptake) translated into
PR with an Odds Ratio (OR) of 60.265 $(95\%-CI$
5.038-720.922). Elevated LDH implied a reduced chance for
partial remission with an OR of 0.094 $(95\%-CI$ 0.017 -
0.518) but increases the frequency of progressive disease
(OR 2.717, $95\%-CI$ 1.391-5.304); All patients who achieved
partial remission had a normal baseline LDH. Factor-2
elevation of CgA increased the risk for progression with an
OR of 3.089 $(95\%-CI$ 1.302 - 7.332). Baseline PSA showed
no significant odds. Conclusion: In our cohort baseline PSA
had no prognostic value for response prediction. LDH was the
marker with the strongest prognostic value and elevated LDH
increased the risk for progression of disease under
PSMA-RLT. Elevated CgA demonstrated moderate impact as a
negative prognostic marker in general but was explicitly
related with the presence of liver metastases. Well in line
with literature, sufficient tumor uptake is a prerequisite
to achieve tumor-response.},
cin = {C060 / E030 / E060},
ddc = {610},
cid = {I:(DE-He78)C060-20160331 / I:(DE-He78)E030-20160331 /
I:(DE-He78)E060-20160331},
pnm = {319H - Addenda (POF3-319H)},
pid = {G:(DE-HGF)POF3-319H},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31653712},
doi = {10.2967/jnumed.119.231431},
url = {https://inrepo02.dkfz.de/record/147386},
}